Skip to main content
Premium Trial:

Request an Annual Quote

Sciex, Advaita Sign Reseller Deal

NEW YORK (GenomeWeb) – Sciex today announced an exclusive reseller agreement with Advaita Bioinformatics that allows Sciex to sell Advaita licenses of iPathwayGuide as part of the OneOmics project.

As part of the deal, Advaita's web-based application for pathway impact analysis will provide Sciex customers with access to iPathwayGuide to interpret Swath Acquisition-based next-generation proteomics data. According to Sciex, only Swath Acquisition bridges the gaps previously found in data research, while Advaita's iPathwayGuide enables researchers to analyze the data using fold change results of mRNA or proteins, and then align the results to evaluate correlations between the two datasets with visualizations and literature references that are publication-ready.

Sciex added that Swath Acquisition also eliminates the so-called "missing data problem" in which shotgun proteomics measures an incomplete set of difficult-to-reproduce proteins. The data acquisition method allows reproducible proteome research to be performed across multiple samples and is further enhanced through integration with next-generation sequencing technologies from Illumina, which is enabled through the OneOmics project.

The project is a partnership between Illumina and Sciex to tear down informatics barriers between different omics-based research. It integrates Swath-based next-generation proteomics and next-generation sequencing data on the BaseSpace cloud computing environment.

"Omics disciplines are converging and, increasingly, researchers are finding that despite impressive advances in specific fields of genomics, proteomics, and metabolomics, the answers to complex biological questions cannot be answered by any one discipline alone," Aaron Hudson, senior director of academic and clinical research business at Sciex said. "This exclusive partnership with Advaita will give researchers the ability to quickly integrate genomics and proteomics results, leading to a greater understanding of systems biology."

Financial and other terms of the deal were not disclosed.